Daniel Sherbenou, MD, Hematology, Aurora, CO, University of Colorado Hospital


Hematology Aurora, CO

Hematologic Oncology

Assistant Professor

Dr. Sherbenou is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sherbenou's full profile

Already have an account?


  • I am a physician scientist at the University of Colorado Anschutz Medical Campus focused on patient care and translational research for multiple myeloma.

Skills & Expertise

  • Hematologic oncology, Laboratory research, Plasma cell disorders, Autologous stem cell transplantation, Translational Research, POEMS syndrome, Monoclonal gammopathy of unknown significance, Waldenstrom's macroglobulinemia

Education & Training

  • UCSF
  • University of Utah
    University of UtahRESIDENCY
  • Oregon Health & Science University School of Medicine
    Oregon Health & Science University School of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2015 - 2021
  • CA State Medical License
    CA State Medical License 2012 - 2015
  • UT State Medical License
    UT State Medical License 2010 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Translational Research Training in Hematology European Hematology Association/American Society of Hematology, 2018
  • Loan Repayment Program National Cancer Institute
  • 2016 Young Investigator Award National Comprehensive Cancer Network (NCCN) Foundation
  • Join now to see all

Publications & Presentations



  • Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples
    Daniel W. Sherbenou, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Colorado tool, My-DST, may pick best multiple myeloma treatment
  • First Person – Shelby Bearrows
    First Person – Shelby BearrowsJuly 01, 2019
  • NCCN Foundation Awards Grants to Five Young Investigators
    NCCN Foundation Awards Grants to Five Young InvestigatorsApril 01, 2016

Grant Support

  • Targeting Cancer Initiating Cells in Multiple MyelomaNational Cancer Institute/National Institutes of Health2018–2023
  • A patient-derived xenograft model of multiple myeloma to test anti-CD46 antibody drug conjugate for curative potential.National Comprehensive Cancer Network (NCCN Foundation2016–2018


  • Committee Member, Protocol Review Committee, University of Colorado Cancer Center 2016 - Present
  • Interviewer/Committee Member, Hematology/Oncology Fellowship Admissions 2016 - Present
  • Co-chair, Cancer Biology Graduate Program Seminar Series 2016 - Present
  • Faculty Mentor, Cancer Biology Graduate Program Retreat Organizing Committee 2016 - Present

Research History

  • Ex Vivo Drug Sensitivity Screening to Personalize Treatment for Multiple Myeloma2016 - Present
  • Targeting Multiple Myeloma with the CD46-Antibody Drug Conjugate2013 - Present
  • Screening for Drug Resistance Mutations in Patients with Chronic Myeloid Leukemia on Treatment with Imatinib/Gleevec2003 - 2007
  • Characterization of Sodium Channel Isoform Expression in the Peripheral Nervous System1995 - 1997
  • Two-Hybrid Screen for SUR2 Interaction Partners in the C.elegans Ras Pathway1994 - 1995

Professional Memberships

Hospital Affiliations